Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)
Proteon Therapeutics (NASDAQ: PRTO) and NeuroDerm (NASDAQ:NDRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Earnings and Valuation
This table compares Proteon Therapeutics and NeuroDerm’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Proteon Therapeutics||N/A||N/A||-$26.35 million||($1.57)||-0.96|
NeuroDerm is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
47.2% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of NeuroDerm shares are owned by institutional investors. 36.3% of Proteon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Proteon Therapeutics and NeuroDerm, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Proteon Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 500.00%. NeuroDerm has a consensus target price of $45.86, suggesting a potential upside of 18.04%. Given Proteon Therapeutics’ higher probable upside, equities analysts plainly believe Proteon Therapeutics is more favorable than NeuroDerm.
This table compares Proteon Therapeutics and NeuroDerm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Proteon Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, NeuroDerm has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
About Proteon Therapeutics
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson’s disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.